blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2357182

EP2357182 - Inhibitors of tyrosine kinases [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  27.03.2015
Database last updated on 10.07.2024
Most recent event   Tooltip08.07.2016Lapse of the patent in a contracting state
New state(s): HU		published on 10.08.2016  [2016/32]
Applicant(s)For:BE  BG  CH  CY  CZ  DE  DK  EE  ES  FI  FR  GB  GR  HU  IE  IT  LI  LU  MC  NL  PT  RO  SE  SI  SK  TR 
Novartis AG
Lichtstrasse 35
4056 Basel / CH
For:AT 
Novartis Pharma GmbH
Brunner Strasse 59
1230 Wien / AT
[2011/33]
Inventor(s)01 / Breitenstein, Werner
Novartis Pharma AG
Postfach
4002 Basel / CH
02 / Furet, Pascal
Novartis Pharma AG Werk Klybeck Postfach
4002 Basel / CH
03 / Jacob, Sandra
Impasse des Lilas 3
68510 Rantzwiller / FR
04 / Manley, Paul W.
Novartis Pharma AG Postfach
4002 Basel / CH
 [2014/21]
Former [2011/33]01 / Breitenstein, Werner
Novartis Pharma AG Postfach
4002 Basel / CH
02 / Furet, Pascal
Novartis Pharma AG Werk Klybeck Postfach
4002 Basel / CH
03 / Jacob, Sandra
Impasse des Lilas 3
68510 Rantzwiller / FR
04 / Manley, Paul W.
Novartis Pharma AG Postfach
4002 Basel / CH
Representative(s)Roth, Peter Richard
Novartis Pharma AG
Patent Department
4002 Basel / CH
[2014/21]
Former [2011/33]Roth, Peter Richard
Novartis Pharma AG Patent Department
4002 Basel / CH
Application number, filing date10174608.904.07.2003
[2011/33]
Priority number, dateGB2002001567605.07.2002         Original published format: GB 0215676
GB2002002989320.12.2002         Original published format: GB 0229893
[2011/33]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2357182
Date:17.08.2011
Language:EN
[2011/33]
Type: B1 Patent specification 
No.:EP2357182
Date:21.05.2014
Language:EN
[2014/21]
Search report(s)(Supplementary) European search report - dispatched on:EP24.06.2011
ClassificationIPC:C07D401/14, C07D405/14, A61K31/506, A61P35/00
[2011/33]
CPC:
C07D401/14 (EP,KR,US); C07D401/04 (KR); A61P11/06 (EP);
A61P13/12 (EP); A61P15/08 (EP); A61P17/06 (EP);
A61P27/02 (EP); A61P3/10 (EP); A61P35/00 (EP);
A61P35/02 (EP); A61P35/04 (EP); A61P37/02 (EP);
A61P37/06 (EP); A61P43/00 (EP); A61P9/00 (EP);
A61P9/10 (EP); C07D405/14 (EP,KR,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2011/33]
TitleGerman:Tyrosin-Kinase-Hemmer[2011/33]
English:Inhibitors of tyrosine kinases[2011/33]
French:Inhibiteurs de kinases de tyrosine[2011/33]
Examination procedure17.02.2012Examination requested  [2012/13]
27.03.2012Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
01.06.2012Amendment by applicant (claims and/or description)
29.05.2013Communication of intention to grant the patent
14.08.2013Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
16.12.2013Communication of intention to grant the patent
09.04.2014Fee for grant paid
09.04.2014Fee for publishing/printing paid
09.04.2014Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP03762632.2  / EP1532138
EP08161965.2  / EP2100891
Divisional application(s)EP10174830.9  / EP2368889
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20030762632) is  08.09.2005
Opposition(s)24.02.2015No opposition filed within time limit [2015/18]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
01.06.2012Request for further processing filed
01.06.2012Full payment received (date of receipt of payment)
Request granted
18.06.2012Decision despatched
Fees paidRenewal fee
03.01.2011Renewal fee patent year 03
03.01.2011Renewal fee patent year 04
03.01.2011Renewal fee patent year 05
03.01.2011Renewal fee patent year 06
03.01.2011Renewal fee patent year 07
03.01.2011Renewal fee patent year 08
12.07.2011Renewal fee patent year 09
13.07.2012Renewal fee patent year 10
10.07.2013Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU04.07.2003
BG21.05.2014
CY21.05.2014
CZ21.05.2014
DK21.05.2014
EE21.05.2014
FI21.05.2014
MC21.05.2014
RO21.05.2014
SE21.05.2014
SI21.05.2014
SK21.05.2014
IE04.07.2014
LU04.07.2014
[2016/32]
Former [2016/31]BG21.05.2014
CY21.05.2014
CZ21.05.2014
DK21.05.2014
EE21.05.2014
FI21.05.2014
MC21.05.2014
RO21.05.2014
SE21.05.2014
SI21.05.2014
SK21.05.2014
IE04.07.2014
LU04.07.2014
Former [2016/25]BG21.05.2014
CZ21.05.2014
DK21.05.2014
EE21.05.2014
FI21.05.2014
MC21.05.2014
RO21.05.2014
SE21.05.2014
SI21.05.2014
SK21.05.2014
IE04.07.2014
LU04.07.2014
Former [2016/21]CZ21.05.2014
DK21.05.2014
EE21.05.2014
FI21.05.2014
MC21.05.2014
RO21.05.2014
SE21.05.2014
SI21.05.2014
SK21.05.2014
IE04.07.2014
LU04.07.2014
Former [2015/37]CZ21.05.2014
DK21.05.2014
EE21.05.2014
FI21.05.2014
RO21.05.2014
SE21.05.2014
SI21.05.2014
SK21.05.2014
IE04.07.2014
LU04.07.2014
Former [2015/36]CZ21.05.2014
DK21.05.2014
EE21.05.2014
FI21.05.2014
RO21.05.2014
SE21.05.2014
SI21.05.2014
SK21.05.2014
LU04.07.2014
Former [2015/13]CZ21.05.2014
DK21.05.2014
EE21.05.2014
FI21.05.2014
RO21.05.2014
SE21.05.2014
SK21.05.2014
LU04.07.2014
Former [2015/11]CZ21.05.2014
DK21.05.2014
EE21.05.2014
FI21.05.2014
RO21.05.2014
SE21.05.2014
SK21.05.2014
Former [2015/10]CZ21.05.2014
DK21.05.2014
EE21.05.2014
FI21.05.2014
SE21.05.2014
SK21.05.2014
Former [2015/08]DK21.05.2014
FI21.05.2014
SE21.05.2014
Former [2014/50]FI21.05.2014
SE21.05.2014
Former [2014/49]FI21.05.2014
Documents cited:Search[Y]EP0588762  (CIBA GEIGY AG [CH]) [Y] 1-14 * page 3, line 52 - line 56; claim 1 *;
 [Y]WO9509853  (CIBA GEIGY AG [CH], et al) [Y] 1-14* the whole document *;
 [XY]  - ZIMMERMANN J ET AL, "Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, (19970121), vol. 7, no. 2, ISSN 0960-894X, pages 187 - 192, XP004135990 [X] 10 * examples 17,24; table 1 * * the whole document * [Y] 1-14

DOI:   http://dx.doi.org/10.1016/S0960-894X(96)00601-4
 [Y]  - ZIMMERMANN J ET AL, "Phenylamino-pyrimidine (PAP) - derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, (19960604), vol. 6, no. 11, ISSN 0960-894X, pages 1221 - 1226, XP004134858 [Y] 1-14 * examples 3,11; table 1 *

DOI:   http://dx.doi.org/10.1016/0960-894X(96)00197-7
 [Y]  - PAUL R ET AL, "Preparation of substituted N-phenyl-4-aryl-2-pyrimidinamines as mediator release inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, (19930917), vol. 36, no. 19, ISSN 0022-2623, pages 2716 - 2725, XP002134022 [Y] 1-14 * examples 2-7,2-22; table II *

DOI:   http://dx.doi.org/10.1021/jm00071a002
by applicantDE3524519
 EP0299497
 JPH10182459
 WO9965874
 WO0119800
 WO0151456
 WO0153274
    - BHAT ET AL., J BIOL CHEM., (1997), vol. 272, pages 16170 - 5
    - SHIBUYA ET AL., ONCOGENE, (1990), vol. 5, pages 519 - 24
    - HOUBEN-WEYL, Methoden der organischen Chemie,4th edition, GEORG THIEME VERLAG, (1974), vol. 15/1
    - T. W. GREENE, Protective Groups in Organic Synthesis, WILEY
    - J. MED. CHEM., (1973), vol. 16, pages 118 - 122
    - ROLF PAUL ET AL., JOURNAL OF MEDICINAL CHEMISTRY, (1993), vol. 36, no. 19, pages 2716 - 25
    - J. MINDL, COLLECT. CZECH. CHEM. COMMUN., (1973), vol. 38, pages 3496 - 505
    - DEAN E. WELCH, J. MED. CHEM., (1969), vol. 12, pages 299 - 303
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.